Novavax reported $-190.71M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 408.21M 17.88M Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
Geron USD 218.61M 10.49M Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
MannKind USD -67.2M 8M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 6.76B 647M Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -190.71M 45.94M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026